Dr. Jou, Yuh-Shan 周玉山 博士

Brand

HIGHLIGHT DETAIL
重要成果詳細內容


HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.

Clin Cancer Res., Jul 18, 2012

Histone deacetylase inhibitors (HDACi) are actively explored as new-generation epigenetic drugs but have low efficacy in cancer monotherapy. To reveal new mechanism for combination therapy, we show that HDACi induce cell death but simultaneously activate tumor-progressive genes to ruin therapeutic efficacy.

Journal Link 期刊連結

List of Highlights
文件紀錄

Top